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INTRODUCTION
Preoperative chemotherapy has become one of the treatment 
options for patients with locally advanced breast cancer [1,2]. 
The National Surgical Adjuvant Breast Project (NSABP) pro-
tocol B-18 was a large, prospectively randomized clinical trial 
designed to compare the effects of doxorubicin and cyclophos-
phamide (AC) administered either preoperatively or in a more 
traditional postoperative regimen. The results of this trial showed 
that more patients could undergo lumpectomy as primary sur-
gical treatment than was initially considered feasible, particu-
larly in those patients whose tumors clinically measured ≥5.1 
cm [3,4].
Breast cancer in Korea continues to rise each year, and it has 
become the most common cancer in Korean women since 2001. 
Breast cancer patients in Korea also have a strong preference 
for breast conserving surgery (BCS). The rate of BCS has been 
increasing each year. However, the rate is relatively lower in 
Korea than in European countries [5]. Preoperative chemo-
therapy has been used to increase the rate of BCS in Caucasian 
women [3,4]. However, whether it would also increase the rate 
of BCS in Korean women has not been verified.
We initiated a phase III randomized study of preoperative 
chemotherapy with AC versus docetaxel/capecitabine (TX) 
for stage II and III breast cancer [6]. We report that this study 
demonstrated that the combination of docetaxel plus capecitabine 
was effective and well tolerated and compares favorably to AC 
as preoperative chemotherapy for the treatment of early breast 
cancer. TX showed a trend toward increased pCR in patients 
with poor prognostic factors and hormone receptor-positive 
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Purpose: Preoperative chemotherapy has been used to increase 
the rate of breast conserving surgery (BCS) in Caucasian women. 
However, whether it would also increase the rate of BCS in         
Korean women has not been verified. The aim of this study was 
to determine the effectiveness of preoperative chemotherapy to 
make BCS possible in Korean women who have locally advanced 
cancer without any increase of locoregional recurrence accord-
ing to operation methods (BCS vs. mastectomy). Methods: From 
August 2002 to April 2005, 205 patients with stage II or III breast 
cancer were enrolled in a phase III randomized trial of preopera-
tive chemotherapy. Surgeons decided on the type of surgery 
(mastectomy or BCS) at initial diagnosis. By randomization, pa-
tients received four cycles of either docetaxel/capecitabine or 
doxorubicin/cyclophosphamide followed by surgery and cross-
over to the other treatment as postoperative chemotherapy.         
Results: The mean tumor size was 3.29 cm and  the mean breast 
volume was 489 cc at diagnosis. After preoperative chemotherapy, 
clinical response was shown in 76.0% of the patients. Of the 71 
patients planned for a mastectomy at initial diagnosis, 27 patients 
underwent BCS (38.0%). Clinical T stage after preoperative che-
motherapy, pathologic T size and lymphatic invasion were corre-
lated with conversion to BCS. In multivariate analysis, only lym-
phatic invasion showed statistical significance. Locoregional dis-
ease-free survival did not statistically differ between the two oper-
ation methods for the patients who were planned for a mastec-
tomy at the initial exam. Conclusion: This study showed that pre-
operative chemotherapy also increased the rate of BCS, while 
avoiding any increase of locoregional recurrence in Korean women 
with locally advanced breast cancer.
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tumors [6].
Therefore, the aim of this study was to determine the effec-
tiveness of preoperative chemotherapy to make BCS possible 
in Korean women who have locally advanced cancer, while 
avoiding any increase of locoregional recurrence according to 
operation methods (BCS vs. mastectomy).
METHODS
Patients’ characteristics
In June 2002, we initiated a phase III randomized study of 
preoperative chemotherapy with AC versus TX for stage II and 
III breast cancer [6]. The study was approved by an Indepen-
dent Review Board at the National Cancer Center of Korea in 
accordance with local regulations and was conducted in accor-
dance with the Declaration of Helsinki. All participating pa-
tients provided us with informed consent.
We used a stratified block randomization of block size four 
according to disease status (stage II or III), estrogen receptor 
status (positive or negative), and age (<50 or ≥50 years).
The study profile is shown in Figure 1. All patients needed 
to have histologically confirmed and newly diagnosed stage II 
and III breast cancer. We used fluorine-18 fluorodeoxyglucose 
positron emission tomography (
18F-FDG-PET) or fine needle 
aspiration biopsy (FNAB) to determine a positive axillary lymph 
node on initial examination. The patients who had received 
hormonal therapy, chemotherapy or radiotherapy for breast 
cancer were previously excluded in this trial. The patients who 
underwent breast operation other than biopsy for diagnosis 
were also excluded. From June 2002 to March 2005, 205 pa-
tients were enrolled in this trial. 
Treatment
The patients underwent preoperative chemotherapy, opera-
tion and postoperative chemotherapy. The surgery consisted of 
either modified radical mastectomy or BCS with axillary lymph 
node dissection. The surgeon decided which type of surgery 
was adequate for each patient at initial diagnosis. Mastectomy 
was decided at initial diagnosis if the patients had a large tumor 
in a small breast, multiple tumors in different quadrants or 
diffusely scattered suspicious microcalcification on the breast. 
Subsequently, patients underwent the preoperative chemother-
apy according to randomization. For 101 patients, doxorubicin 
(60 mg/m
2)/cyclophosphamide (600 mg/m
2) was administered 
intravenously on day 1 of each 3-week cycle. For 103 patients, 
docetaxel 36 mg/m
2 was administered as intravenous infusion 
on day 1 of each 3-week cycle along with capecitabine 1,000 
mg/m
2 p.o. b.i.d. on days 1–14. The cycle was repeated 4 times, 
every 3 weeks. If the patients refused the chemotherapy or     
received chemotherapy with dose-reduction, we excluded these 
patients in this study. Operation followed within 3 weeks after 
the fourth cycle of the preoperative chemotherapy. If patients 
showed closed margin status (<2 mm) in the pathologic report, 
the surgeons performed further excision on the patients. Post-
operative chemotherapy was given as follows: AC for 4 cycles 
for the patients who received TX before surgery and TX for 4 
cycles for the patients who received AC before surgery. After 
completion of postoperative chemotherapy, all patients received 
radiotherapy and concurrently endocrine therapy with tamox-
ifen or anastrozole when the hormonal receptor was positive. 
The patients who clinically showed lymph node metastasis also 
received radiotherapy, although they underwent modified radi-
cal mastectomy.
Patients’ evaluations
Clinical response was assessed using the response evaluation 
criteria in solid tumors (RECIST) criteria [7]. Baseline exami-
nations were performed prior to the first cycle of chemotherapy 
and included a physical examination, PET with 18-fluorode-
oxyglucose (FDG-PET) or PET combined with computed     
Biopsy-proven, newly diagnosed stage II/III breast cancer 
Axillary lymph node involvement 
No prior surgery, hormonal, chemo- or rediotherapy
106 assigned to TX and 
received TX
103 assigned to AC 
and received AC
103 received AC 101 received TX
Surgeons decided which type of surgery 
was adequate for the patients
Response evaluation by RECIST
204 patients analyzed
204 underwent operation; Two patients refused further therapy 
after the first cycle of TX, and one patient refused operation  
after the fourth cycle of TX. Two patients refused further  
chemotherapy or operation after the third cycle of AC
209 patients signed a consent form and randomized
Figure 1. Study profile.
TX=docetaxel+capecitabine; AC=doxorubicin+cyclophosphamide; 
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tomography (CT) to exclude node-negative and stage IV dis-
ease, and ultrasound to determine tumor size as described in 
the previously published paper [6]. All the focal FDG accumu-
lations for the ipsilateral, contralateral axillary, internal mam-
mary, supraclavicular and infraclavicular nodal groups and for 
any extranodal foci were identified. Focal FDG accumulations 
above 1 mL/g in standardized uptake value, which could not 
be explained by overt inflammation, were diagnosed positive 
for metastases [8-10]. Ultrasound of the affected breast was 
repeated prior to the third cycle of chemotherapy and surgery 
to evaluate tumor and lymph node size. Partial and complete 
responses were confirmed with repeat imaging as described 
in the previously published paper [6]. Clinical stage was deter-
mined according to the 6th edition of American Joint Commit-
tee on Cancer (AJCC). Breast volume was calculated by CT in 
100 patients available before preoperative chemotherapy, and 
was calculated by the summation of segmented monolayers. 
Locoregional recurrence is defined if the patients showed the 
recurrence on the ipsilateral breast and axillary lymph node.
Statistical analysis
To determine the correlating factors to BCS, univariate com-
parisons of the study variables were assessed by chi-square 
tests for categorical variables and t-test for continuous vari-
ables. Multivariate analysis was also performed to estimate 
correlating factors with conversion to BCS in patients who 
were planned for mastectomy at initial diagnosis. Kaplan-Meier 
curves were used to calculate locoregional disease-free survival. 
For an operation method group comparison, a log-rank test 
was used in the survival analysis. All statistical analyses were 
performed with STATA version 10.0 (StataCorp LP, College 
Station, USA). 
RESULTS
Patients’ characteristics
The median age was 44.0 years (range, 21-67 years), and the 
mean tumor size was 3.29 cm (range, 0.9-12 cm) at initial diag-
nosis and 1.71 cm (range, 0.0-8.0 cm) after 4 cycles of preop-
erative chemotherapy. The mean reduction of tumor size was 
1.58 cm. The mean breast volume was 489 cc. At initial diag-
nosis, the surgeon planned mastectomy in 71 patients (34.8%). 
After 4 cycles of CTx, the surgeon performed mastectomy in 
61 patients (29.9%) and BCS in 143 patients (70.1%). After 4 
cycles of preoperative chemotherapy, clinical response was shown 
in 76.0% (CR, 4.4%; PR, 71.6%) by the RECIST criteria. Tables 
1 and 2 show the patients’ characteristics and clinical tumor 
response in this study. 
Table 1. Patients’ characteristics
Characteristics No. %
Age (yr)*  44 (21-67)
Clinical tumor size at initial diagnosis (cm)
†   3.29 (0.9-12.0)
Clinical tumor size after CTX (cm)
† 1.71 (0.0-8.0)
Breast volume (cc)
†    489 (27-1370)
Menopausal stage
   Premenopausal 128 62.7
   Postmenopausal   76 37.3
Multicentricity
   Single 158 77.4
   Multifocality   22 10.8
   Multicentricity   24 11.8
Clinical T stage
   T1   33 16.2
   T2 128 62.7
   T3   25 12.3
   T4   18   8.8
Clinical Nodal stage
   N1 119 58.3
   N2   67 32.8
   N3   18   8.8
Clinical stage
   IIA   22 10.8
   IIB   89 43.6
   IIIA   60 29.4
   IIIB   15   7.4
   IIIC   18   8.8
Hormonal receptor status
   ER+/PR+ 102 50.0
   ER+/PR-   22 10.8
   ER-/PR+     2   1.0
   ER-/PR-   78 38.2
HER2 receptor status
   HER2+++   58 28.4
   HER2++ 106 52.0
   HER2-/+   40 19.6
Planned operation at initial diagnosis
   Mastectomy   71 34.8
   BCS 133 65.2
Performed operation after 4 cycles CTx
   Mastectomy   61 29.9
   BCS 143 70.1
ER=estrogen receptor; PR=progesterone receptor; BCS=breast conserving 
surgery; CTx=chemotherapy.
*Median (range); 
†Mean (range).
Table 2. Clinical tumor response after 4 cycles of preoperative chemo-
therapy
Tumor response
Overall
(n=204)
Patients planned for  
a mastectomy
at initial diagnosis
(n=71)
Complete response   9 (4.4) 1 (1.4)
Partial response 146 (71.6) 55 (77.5)
No response   49 (24.0) 15 (21.1)
All values represent number (%).292  SeeyounLee,etal.
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Effectiveness of preoperative chemotherapy to make BCS 
possible
The surgeons decided the operation method for the enrolled 
patients at initial diagnosis. They planned mastectomy for 71 
patients at initial diagnosis. After 4 cycles of preoperative che-
motherapy, they performed BCS in 27 patients among the 71 
patients with a planned mastectomy at initial diagnosis. The 
conversion rate was estimated at 38.0% (Table 3).
Correlating factors to BCS in all 204 patients
In all 204 patients, T stage, tumor size, N stage, and TNM 
stage at initial diagnosis were the factors correlated with BCS 
on univariate analysis. Microcalcification on mammography, 
multicentricity of tumor, tumor size, T stage, N stage, TNM 
stage in pathologic finding and lymphatic invasion were also 
correlating factors with BCS on univariate analysis (Table 4). 
However, multivariate analysis showed that multicentricity, T 
stage and N stage in the pathologic finding were significantly 
correlated with BCS (Table 5).
Factors correlated with conversion to BCS after preoperative 
chemotherapy
In 71 patients with a planned mastectomy at initial diagnosis, 
T stage at initial diagnosis, lymphatic invasion, tumor size and 
TNM stage in the pathologic finding were correlated with con-
version to BCS after preoperative chemotherapy on univariate 
analysis (Table 4). Among these, lymphatic invasion was only 
significantly correlated with conversion to BCS on multivariate 
analysis (Table 6).
Locoregional disease-free survival according to operation method
The mean follow-up time was 52.3 months (range, 5-74 
months). Locoregional disease-free survival did not statistically 
differ between the two groups (performed BCS vs. performed 
mastectomy) in the patients with a planned mastectomy at initial 
exam (p=0.649). 
 
DISCUSSION
In this section, we analyze the effectiveness of preoperative 
Table 3. Difference of operative methods between initial plan and per-
formance after preoperative chemotherapy
Methods
Planned  
mastectomy 
(n=71)
Planned  
BCS  
(n=133)
Total  
(n=204)
Performed mastectomy 44 (62.0)   17 (12.8)   61 (29.9)
Performed BCS 27 (38.0) 116 (87.2) 143 (70.1)
BCS=breast conserving surgery.
All values represent number (%).
Table 4. Correlating factors to breast conserving surgery by univariate 
analysis
Factors        
p-value
Overall  
(n=204)
Patients planned
for a mastectomy
(n=71)
Menopause 0.875 0.419
Age 0.095 0.883
Clinical T stage at initial diagnosis 0.001 0.042
Clinical tumor size at initial diagnosis 0.001 0.095
Clinical N stage at initial diagnosis 0.003 0.365
Clinical stage at initial diagnosis 0.001 0.280
Clinical T stage after CTx 0.001 0.373
Clinical tumor size after CTx 0.001 0.110
Clinical N stage after CTx 0.034 0.417
Clinical stage after CTx 0.002 0.109
Microcalcification on MMG 0.033 0.243
Multicentricity 0.001 0.160
Pathologic tumor size 0.001 0.002
Pathologic T stage 0.001 0.081
Pathologic N stage 0.011 0.130
Pathologic stage 0.001 0.019
Histologic grade 0.585 0.891
ER status 0.120 0.533
PR status 0.544 0.284
Vascular invasion 1.000 0.264
Lymphatic invasion 0.002 0.001
EIC 0.585 0.458
CTx=chemotherapy; MMG=mammography; ER=estrogen receptor; PR= 
progesterone receptor; EIC=extensive intraductal component.
Table 5. Correlating factors to breast conserving surgery in all 204 pa-
tients by multivariate analysis
Factors
95% CI
  p-value
Lower Upper
Clinical T stage after CTx 0.841   6.226   0.105
Pathologic T stage 0.004   0.686   0.025
Pathologic N stage 0.006   0.461   0.008
Pathologic stage 0.989 10.782   0.052
Multicentricity 1.012   2.602   0.045
Lymphatic invasion 0.560   6.120   0.313
CI=confidence interval; CTx=chemotherapy.
Table 6. Correlating factors to breast conserving surgery in 71 patients 
planned for a mastectomy at initial diagnosis by multivariate analysis
Factors
95% CI
  p-value
Lower Upper
Clinical T stage after CTx 0.869   3.373   0.120
Pathologic stage 0.573   2.621   0.601
Lymphatic invasion 1.599 71.885   0.015
CI=confidence interval; CTx=chemotherapy.BCSinKoreanWomenafterChemotherapy 293
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chemotherapy to make BCS possible in Korean women. A large 
number of consecutive patients who had locally advanced breast 
cancer and planned preoperative chemotherapy and operation 
were enrolled in this prospectively designed, single-institute 
study. This study differs from other studies in that our study 
might be the first efficiently designed trial about the effective-
ness of preoperative chemotherapy to make BCS possible in 
Korean women who have advanced cancer. We decided which 
type of surgery was adequate for the patients at initial diagnosis. 
Subsequently, patients underwent the preoperative chemother-
apy according to randomization and operation. Twenty-seven 
patients among 71 patients (38%) who could not avoid mastec-
tomy at initial diagnosis underwent BCS after preoperative 
chemotherapy. Although 17 patients could undergo BCS at 
initial diagnosis, they sought mastectomy after preoperative 
chemotherapy. 
In a number of important randomized trials (National Surgi-
cal Adjuvant Breast and Bowel Project [NSABP] B-18, NSABP 
B-27, Mauriac et al., Scholl et al., European Organization for 
Research and Treatment of Cancer [EORTC] 10902, Petrov 
Institute, Powles et al.) patients with breast cancer were evalu-
ated and chemotherapy was compared in the preoperative or 
the postoperative setting [3,11-18]. From these trials, the effec-
tiveness of preoperative chemotherapy on operation method 
was also reported. The NSABP B-18 trial was the first study to 
compare postoperative with preoperative chemotherapy. The 
NSABP protocol B-18 reported that the size of primary breast 
tumors was clinically reduced in 80% of patients treated pre-
operatively and no tumor could be detected clinically in 36% 
of the patients [3,4]. The trial resulted in a 7% higher rate of 
BCS compared with the postoperative treatment arm (60% vs. 
67%, p<0.01) [3]. The European Cooperative Trial in operable 
breast cancer (ECTO) showed an increase in BCS from 34% in 
the postoperative treatment arm to up to 65% by preoperative 
chemotherapy (p<0.001) [19]. The EORTC 10902 trial also 
demonstrated an improvement in the BCS rate by preoperative 
chemotherapy: 21% (postoperative treatment arm) vs. 37% (pre-
operative treatment arm) [16]. Moreover, the EORTC 10902 
trial showed that 23% underwent BCS among the patients who 
were planned for mastectomy in the preoperative chemotherapy 
group [16]. Our study showed that the conversion rate to BCS 
was 38%. This result translates into a successful effect of pre-
operative chemotherapy in this study compared with other 
studies in Westernized countries. A few studies have been       
reported on BCS after preoperative chemotherapy for Asian 
patients [20,21]. However, in these studies, relatively small num-
bers of patients (30 patients) were enrolled compared with our 
study (204 patients). We also enrolled stage IIA patients in this 
study, although all of these were patients with T1N1M0. 
Another study has reported three preoperative factors that 
are the main predictors for breast conservation: the existence of 
microcalcification as seen in the pretreatment mammography, 
the postchemotherapy tumor size, and the type of mammo-
graphic lesions [22]. Clinical tumor sizes, nodal status and clini-
cal CR were demonstrated as the correlating factors with BCS 
in the NASBP B-18 trial [3]. We showed that multicentricity, T 
stage and N stage in the pathologic finding were significantly 
correlated with BCS performed in all 204 patients (Table 5). 
The presence of tumor multicentricity may be correlated with 
the possibility of a diffuse tumor extent and the preoperative 
chemotherapy may not be effective in this case. Advanced T 
stage in the pathologic finding can also translate into a poor 
response to preoperative chemotherapy and the tumor may 
not shrink effectively with preoperative chemotherapy. How-
ever, Table 6 shows that lymphatic invasion was only the signif-
icant correlating factor with conversion to BCS in patients who 
were appropriate for mastectomy at initial diagnosis. However, 
the reason why the lymphatic invasion is only one factor corre-
lating with conversion is not clear. 
We planned mastectomy at the initial exam for the patients 
who showed multifocal tumor and diffuse suspicious micro-
calcification. After preoperative chemotherapy, we could not 
change the mastectomy into breast conversion surgery in these 
patients. The preoperative chemotherapy may not be effective 
on these cases. Seven patients showed a closed margin or posi-
tive margin in the pathologic report. They underwent re-exci-
sion to obtain a safe margin status. However, we did not mas-
tectomy in these patients. 
We used an ultrasonogram to measure the size of the tumor 
before preoperative chemotherapy and after preoperative che-
motherapy in this study. We also used the ultrasonogram to 
measure the size in the patients who showed a multifocal tumor. 
However, in their mammography, some patients showed diffuse 
suspicious microcalcification with a mass. We also used mam-
mography to measure the size of the tumor in a number of these 
patients. 
We found no significant difference in locoregional disease-
free survival according to operation method after preoperative 
chemotherapy in the patients with a planned mastectomy at the 
initial exam. This result is similar to the previously reported 
studies in which patients underwent surgery followed by post-
operative chemotherapy [23-25]. In a preoperative chemother-
apy setting, some studies showed a higher local recurrence rate 
in the mastectomy group than in BCS group. Veronesi et al. [26] 
reported that the local recurrence rate was 5.9% and 21.7% in 
the BCS and mastectomy groups, respectively. McIntosh et al. 
[27] also reported that the local recurrence rate was 2% and 
7% in the BCS and mastectomy groups, respectively. However, 294  SeeyounLee,etal.
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Touboul et al. [28] showed no significant difference in local 
recurrence survival between the BCS and mastectomy groups 
after preoperative chemotherapy. Surgeons have been concerned 
that down-staged tumor by preoperative chemotherapy might 
result in satellite nodules rather than concentric shrinkage and 
they may prefer mastectomy to BCS for locally advanced pa-
tients. However, no significant difference was shown in locore-
gional recurrence in our study. The NSABP B-18 study showed 
no statistically significant differences in disease-free survival 
and overall survival between the preoperative chemotherapy 
group and the postoperative chemotherapy group after 16 years 
follow-up [29].
We attempted to calculate breast volume by CT before pre-
operative chemotherapy. This was calculated by the summation 
of segmented monolayers. Because the qualities of image data 
were poor in some patients, we could only calculate breast vol-
ume in 100 patients. 
In this study, preoperative chemotherapy would also be effec-
tive to raise the rate of BCS in Korean women who have locally 
advanced breast cancer. However, locoregional disease-free 
survival did not statistically differ between BCS and mastectomy 
after preoperative chemotherapy. Therefore, more opportunity 
may be considered to undergo BCS in Korean patients who 
have locally advanced cancer by preoperative chemotherapy. 
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